ALK+ Non–Small Cell Lung Cancer

Jessica J. Lin, MD


January 21, 2020

The most common type of lung cancer is non–small cell lung cancer (NSCLC), and approximately 5% of patients with NSCLC have anaplastic lymphoma kinase gene rearrangements (ALK+). ALK+ NSCLC tumors are sensitive to ALK inhibitors, including crizotinib, which is widely used as first-line treatment in this setting. However, patients typically develop resistance to crizotinib therapy within a year.

Several newer tyrosine kinase inhibitors, including ceritinib, alectinib, brigatinib, and lorlatinib, are now available for the treatment of advanced ALK+ NSCLC. Dr Jessica Lin of Harvard discusses the available options and considerations for choosing an appropriate second- or third-line therapy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.